![Controversial Covaxin study faces retraction after ICMR objection. Image X. Controversial Covaxin study faces retraction after ICMR objection. Image X.](/_next/image?url=https%3A%2F%2Fapi.newsarenaindia.com%2F%2Fuploads%2Funtitled-design-20240520t171239778jpg_1716209006108.jpg&w=3840&q=8)
May 20, 2024, 05:43 AM - 3 mins read
The Indian Council of Medical Research (ICMR) has disassociated itself from a study on the Covaxin vaccine, citing serious methodological flaws and an erroneous acknowledgment of ICMR's support.
Read more![Bharat Biotech has reiterated the robust safety profile of its anti-COVID-19 vaccine, Covaxin, following a study by Banaras Hindu University (BHU) indicating that nearly one-third of 926 individuals who received the vaccine reported 'adverse events of special interest' (AESI). Bharat Biotech has reiterated the robust safety profile of its anti-COVID-19 vaccine, Covaxin, following a study by Banaras Hindu University (BHU) indicating that nearly one-third of 926 individuals who received the vaccine reported 'adverse events of special interest' (AESI).](/_next/image?url=https%3A%2F%2Fapi.newsarenaindia.com%2F%2Fuploads%2Funtitled-design-20240517t122452851jpg_1715929201814.jpg&w=3840&q=8)
May 17, 2024, 12:00 AM - 2 mins read
The BHU study, conducted between January 2022 and August 2023, found that serious AESIs, including stroke and Guillain-Barre syndrome, were reported in 1 percent of the individuals. The study highlighted that nearly 50 percent of participants experienced infections during the follow-up period, predominantly viral upper respiratory tract infections.
Read more![Covaxin is Very Safe Reaffirms Bharat Biotech. Image X. Covaxin is Very Safe Reaffirms Bharat Biotech. Image X.](/_next/image?url=https%3A%2F%2Fapi.newsarenaindia.com%2F%2Fuploads%2Funtitled-design-20240502t195538842jpg_1714660010676.jpg&w=3840&q=8)
May 2, 2024, 07:26 AM - 2 mins read
Amid concerns surrounding the AstraZeneca-Oxford COVID-19 vaccine, Bharat Biotech, the developer of Covaxin, underscores its commitment to safety, emphasising that Covaxin was developed with a primary focus on safety first.
Read more